Tiotropium versus placebo for inadequately controlled asthma: a meta-analysis
| Autor: | Rui Chen, Jin-wu Chen, Jing-wei Tian, Xin Chen |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Pulmonary and Respiratory Medicine
Pediatrics medicine.medical_specialty Evening Vital Capacity Scopolamine Derivatives Critical Care and Intensive Care Medicine Placebo Severity of Illness Index Placebos Forced Expiratory Volume medicine Humans Tiotropium Bromide Adverse effect Asthma Randomized Controlled Trials as Topic business.industry Standard treatment General Medicine Odds ratio medicine.disease respiratory tract diseases Bronchodilator Agents Clinical trial Spirometry Meta-analysis Quality of Life Drug Therapy Combination business |
| Zdroj: | Respiratory care. 59(5) |
| ISSN: | 1943-3654 |
| Popis: | This meta-analysis was performed to evaluate the efficacy and safety of the addition of tiotropium to standard treatment regimens for inadequately controlled asthma.A systematic search was made of PubMed, EMBASE, MEDLINE, and CENTRAL databases, and ClinicalTrials.gov, and a hand search of leading respiratory journals. Randomized, double-blind clinical trials on the treatment of inadequately controlled asthma for ≥ 4 weeks with the addition of tiotropium, compared with placebo, were reviewed. Studies were pooled to odds ratio (OR) and weighted mean differences (WMDs), with 95% CI.Six trials met the inclusion criteria. The addition of tiotropium, compared with placebo, significantly improved all spirometric indices, including morning and evening peak expiratory flow (WMD 20.59 L/min, 95% CI 15.36-25.81 L/min, P.001; and WMD 24.95 L/min, 95% CI 19.22-30.69 L/min, P.001, respectively), trough and peak FEV1 (WMD 0.13 L, 95% CI 0.09-0.18 L, P.001; and WMD 0.10 L, 95% CI 0.06-0.14 L, P.001, respectively), the area under the curve of the first 3 h of FEV1 (WMD 0.13 L, 95% CI 0.08-0.18 L, P.001), trough and peak FVC (WMD 0.1 L, 95% CI 0.05-0.15 L, P.001; and WMD 0.08 L, 95% CI 0.04-0.13 L, P.001, respectively), the area under the curve of the first 3 h of FVC (WMD 0.11 L, 95% CI 0.06-0.15 L, P.001). The mean change in the 7-point Asthma Control Questionnaire score (WMD -0.12, 95% CI -0.21 to -0.03, P = .01) was markedly lower in tiotropium group, but not clinically important. There were no significant differences in Asthma Quality of Life Questionnaire score (WMD 0.09, 95% CI -0.01 to 0.20, P = .09), night awakenings (WMD 0.00, 95% CI -0.05 to 0.05, P = .99) or rescue medication use (WMD -0.18, 95% CI -0.36 to 0.00, P = .06). No significant increase was noticed in adverse events in the tiotropium group (OR 0.80, 95% CI 0.62-1.03, P = .08).The addition of tiotropium to standard treatment regimens has significantly improved lung function without increasing adverse events in patients with inadequately controlled asthma. Long-term trials are required to assess the effects of the addition of tiotropium on asthma exacerbations and mortality. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|